PubMed holds 169 randomized-trial papers and 283 reviews on semaglutide and weight. FDA says compounded versions are not approved, and warns against products labelled for research use.
Whitepill finding
On 2 November 2026, PubMed held 169 randomized-trial papers and 283 reviews on semaglutide and weight. FDA says compounded drugs are not FDA approved, and as of 31 May 2026 it had 990 adverse event reports on compounded semaglutide. Counts show depth of record, not benefit.
The short version
They sayCompounded semaglutide is the same drug, just cheaper.
FDA says compounded drugs are not FDA approved, and that unapproved versions do not undergo its review for safety, effectiveness and quality before marketing. See the receipt
They sayA "research use only" label makes it legal to take.
FDA warns about products falsely labelled for research purposes or not for human consumption, and urges consumers not to buy them. See the receipt
They sayLots of trials means it is safe for everyone.
A trial count is depth of record. The label lists real risks, including a boxed warning about thyroid tumors. See the receipt
Semaglutide is an injected prescription drug that MedlinePlus says is used to assist with weight loss in certain people who are obese or overweight and have weight-related medical problems.[1] Whether that describes any particular person is a question for a clinician.
Two other versions turn up in the scene: compounded copies and products sold for "research". They are not the same thing, and the FDA section below says why.
PubMed holds 169 papers typed as randomized controlled trials and 283 systematic reviews or meta-analyses for semaglutide with obesity, weight loss, weight management or overweight.[2]
The tag is PubMed's own publication type.[3] That is a deep record by the evidence ladder's standard, but it says nothing about who was studied or how large any effect was.
ClinicalTrials.gov lists 412 interventional studies matching semaglutide with obesity, overweight or weight loss.[4] A registration is a plan on file, and we have not assessed any of them.
FDA says compounded drugs are not FDA approved, and that unapproved versions do not undergo its review for safety, effectiveness and quality before they are marketed.[5] It says dosing errors resulted from patients measuring and self-administering incorrect doses.
It also warns about products falsely labelled "for research purposes" or "not for human consumption", and urges consumers not to buy them. For how the same label logic works for peptides, see how FDA's peptide categories work.
On ingredients, FDA says retatrutide and cagrilintide cannot be used in compounding under federal law. It says salt forms should not be used to compound semaglutide, and that it is not aware of any lawful basis for their use in compounding.
1. Which product exactly? Approved, compounded, or "research use" are three different things. 2. A "research use" or "not for human consumption" label is a red flag, not a loophole. FDA says so. 3. Check who prescribes it and who dispenses it. 4. Read the regulator's risk list before the before-and-after photos. 5. This is a prescribing question: a clinician decides.
MedlinePlus says semaglutide injection may increase the risk of thyroid gland tumors, including a type of thyroid cancer, and lists nausea, vomiting and diarrhea among common side effects.[1] It says not to stop using it without talking to your doctor, and that your doctor will tell you to stop it for 2 months before a planned pregnancy.
Those are the approved product's cautions, not an estimate for you. A prescriber weighs them against your history, and they say nothing about a compounded or research-use product, which FDA says has not been reviewed.
Counts are PubMed records matching a published title and abstract query plus a publication-type filter, and ClinicalTrials.gov interventional studies matching the stated terms, both read 2 November 2026. FDA statements are quoted or closely paraphrased from its page, current as of 1 October 2026, and MedlinePlus statements from its page, last revised 15 May 2026, both read in full on 2 November 2026.
Queries are broad and will include off-topic papers, and publication-type tags can be loose, so treat the counts as depth of record (our grading rules are on the methodology page, and every comparison lives on the ladder hub). The FDA report counts are reports, not proof of harm. Nothing here measures effect size, covers dosing, sourcing or compounding, or is medical advice.
(semaglutide[tiab] AND (obesity[tiab] OR "weight loss"[tiab] OR "weight management"[tiab] OR overweight[tiab]))semaglutide AND (obesity OR overweight OR weight loss), interventional studiesPubMed held 169 papers typed as randomized controlled trials and 283 systematic reviews or meta-analyses for semaglutide with obesity, weight loss, weight management or overweight on 2 November 2026.
No. FDA says compounded drugs are not FDA approved, and that unapproved versions do not undergo its review for safety, effectiveness and quality before they are marketed.
FDA warns about products falsely labelled for research purposes or not for human consumption and urges consumers not to buy them.
It says the drug may increase the risk of thyroid gland tumors, including a type of thyroid cancer, and lists nausea, vomiting and diarrhea among common side effects. A prescriber is the right person to discuss them with.
Semaglutide has a deep trial record as an approved prescription drug, and FDA says compounded copies and research-use products have not had its review. Use the count to see that the record exists, then ask a clinician about you.